Mounjaro (Eli Lilly) is expected to face US generic competition from 2036. Lilly 10-K: US compound patent expires 2036. Excludes Zepbound, the same molecule sold for obesity.
Mounjaro's US exclusivity date is based on company guidance. The date comes from the company's own filings or guidance. Secondary patents, new formulations or litigation can still move it. It is a peptide regulated as a drug rather than a biologic, so copies are generics. Peptides are harder to copy than typical pills, so generic uptake can be slower.
Mounjaro is 35% of Eli Lilly's 2025 revenue ($23.0B of $65.2B). With Trulicity, the drugs tracked here add up to 42% of Eli Lilly's revenue losing US exclusivity by 2036.
Bars show each company's tracked drugs as a share of its total 2025 revenue. Mounjaro is highlighted.